Seattle-based Sound Pharmaceuticals said today that its scientists, along with collaborators at UCLA, have found a new molecular target of interest for the treatment of hearing loss. The target, p27Kip1, was described this week in a presentation at the Association for Research in Otolaryngology. Sound Pharmaceuticals said it is seeking to build on this research by developing a local injection designed to inhibit this target, as a way to restore hearing.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
